Here are the S-3 shelf registrations from Crescent Biopharma, Inc. (CBIO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow CBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CBIO filings page.
Crescent Biopharma, Inc. filed a shelf registration to offer up to $500,000,000 of securities and a sales agreement prospectus to sell up to $200,000,000 of ordinary shares under an Open Market Sale agreement with Jefferies LLC.
The $200 million sales agreement amount is included in the $500 million shelf; offerings are subject to completion and may be sold from time to time in one or more offerings. The prospectus notes the company’s ordinary shares trade on Nasdaq under the symbol CBIO, with a last reported sale price of $18.00 per share on June 30, 2026.